Therapeutic targeting of EGFR in colorectal cancer as a novel approach to predict and enhance tumor antigenicity and response to checkpoint inhibitors
Dauer: 54 Monate, Fördersumme: € 999.500
Geräte und Software für Core Facilities
Fördersumme: € 61.255